Suppr超能文献

石蜡包埋浸润性乳腺癌中HER-2/neu蛋白定量表达、DNA倍体以及形态学和临床特征的长期比较预后价值

Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.

作者信息

Baak J P, Chin D, van Diest P J, Ortiz R, Matze-Cok P, Bacus S S

机构信息

Department of Pathology, Free University Hospital, Amsterdam, The Netherlands.

出版信息

Lab Invest. 1991 Feb;64(2):215-23.

PMID:1671789
Abstract

Data regarding the prognostic value of HER-2/neu protein expression in breast cancer are conflicting, perhaps because of short follow-up and technical difficulties in the determination (the admixture of benign elements with the biochemical method and the subjectivity of the immunohistochemical assessment). Therefore, using digital image processing, we compared the correlation between and the prognostic value of (a) quantitative immunohistochemical HER-2/neu protein expression and (b) clinical, morphometric, and flow-cytometric DNA ploidy features; histologic grade; and biochemically assessed estrogen receptor content. Paraffin-embedded invasive breast Pancers of 82 patients with long-term follow-up were used. None of the patients had received adjuvant systemic therapy. HER-2/neu protein expression was significantly correlated with DNA index, lymph node status, and tumor size and, in the diploid tumors, was weakly correlated with the percentage of S-phase cells. Strong HER-2/neu protein expression was associated with a worse prognosis (although not significantly, p = 0.07). No differences were detected between cancers with or without axillary lymph node metastases. In survival analysis, the Multivariate Prognostic Index and the morphometric features were much stronger prognosticators than HER-2/neu protein overexpression, which, however, had additional prognostic value to that of many of the features analyzed, especially when more than 35% HER-2/neu protein levels (relative to the high expression SKBR3 cell line) were present. Combined diploidy and HER-2/neu protein content greater than 35% occurred in a small group of patients (n = 3), all of whom died. Likewise, in tetraploid cancers a combination of S-phase cells greater than or equal to 7% and HER-2/neu protein content greater than 35% was an ominous sign. In multivariate analysis, strong HER-2/neu protein overexpression was prognostically over-shadowed by the morphometric features. Nevertheless, it is important to further analyze the intriguing possibility of identifying a subgroup of breast cancer patients with a very poor outcome merely using cytometric analysis of paraffin-embedded material of the primary tumor.

摘要

关于HER-2/neu蛋白表达在乳腺癌中的预后价值的数据存在矛盾,这可能是由于随访时间短以及检测存在技术困难(生化方法中良性成分的混杂以及免疫组化评估的主观性)。因此,我们利用数字图像处理技术,比较了(a)免疫组化定量HER-2/neu蛋白表达与(b)临床、形态学和流式细胞术DNA倍体特征;组织学分级;以及生化评估的雌激素受体含量之间的相关性及其预后价值。我们使用了82例有长期随访的石蜡包埋浸润性乳腺癌患者。所有患者均未接受辅助全身治疗。HER-2/neu蛋白表达与DNA指数、淋巴结状态和肿瘤大小显著相关,在二倍体肿瘤中,与S期细胞百分比弱相关。HER-2/neu蛋白强表达与较差的预后相关(尽管不显著,p = 0.07)。有或无腋窝淋巴结转移的癌症之间未检测到差异。在生存分析中,多变量预后指数和形态学特征比HER-2/neu蛋白过表达更能有力地预测预后,然而,HER-2/neu蛋白过表达对许多分析特征具有额外的预后价值,特别是当HER-2/neu蛋白水平超过35%(相对于高表达的SKBR3细胞系)时。一小部分患者(n = 3)出现二倍体和HER-2/neu蛋白含量大于35%的组合,所有这些患者均死亡。同样,在四倍体癌症中,S期细胞大于或等于7%与HER-2/neu蛋白含量大于35%的组合是一个不祥之兆。在多变量分析中,形态学特征在预后方面使HER-2/neu蛋白强过表达黯然失色。然而,仅通过对原发性肿瘤石蜡包埋材料进行细胞计数分析来识别预后极差的乳腺癌患者亚组这一有趣的可能性,仍有必要进一步分析。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验